Free Nephrology CME

  • FREE

    ScientiaCME Immunology (Kidney Transplant Rejection)

    ScientiaCME Immunology contains a single lecture:
    Therapeutic Updates, Best Practices, and Barriers to Care in the Treatment and Prevention of Kidney Transplant Rejection.

    Target Audience:
    Physicians specializing in Immunology, Nephrology, Urology

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release
  • FREE

    Fabry disease: Updates from the 15th Annual WorldSymposium

    Fabry disease is characterized by a deficiency of the glycoside hydrolase enzyme alpha galactosidase A, resulting in the accumulation of the glycolipid globotriaosylceramide throughout the body, particularly prominently in the blood vessels.

    After completing Fabry disease: Updates from the 15th Annual WorldSymposium, physicians will better be able to:

    • Describe the pathogenesis, clinical presentations, complications, and epidemiology of Fabry disease including updated material presented at the 15th Annual WORLDSymposium
    • Describe principles and problems regarding screening for and diagnosing Fabry disease that can applied to patient cases
    • Describe emerging therapies for Fabry disease based on research presented at the 15th Annual WORLDSymposium
    • Design and implement appropriate therapeutic plans for treatment of Fabry disease based on research presented at the 15th Annual WORLDSymposium

     

    Target Audience: cardiologists, nephrologists, pediatricians, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists; and any other healthcare professionals with an interest in or who may clinically encounter patients with Fabry disease.

    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: April 18, 2019
    • Expiration of CME credit: April 18, 2020
  • FREE

    Atypical hemolytic uremic syndrome (aHUS): therapeutic updates and optimizing treatment

    Atypical hemolytic uremic syndrome (aHUS) is a disease in which the complement system is activated in an uncontrolled manner outside the presence of coexisting disease, resulting in platelet activation, damage to endothelial cells, and a range of clinical sequelae including: which may ultimately lead to kidney failure; systemic thrombotic microangiopathy;anemia; and thrombocytopenia.

    After completing this course, you will better be able to:

    • Describe the pathophysiology of aHUS such that it might informs pairing with present treatment mechanisms
    • Describe aHUS diagnostic methods, differential diagnosis, and the benefits of earlier diagnosis
    • Describe available therapies used for treatment of aHUS and summarize the literature supporting use of those therapies
    • Design an evidence-based treatment plan for a patient with aHUS

    Target Audience: hematologists, nephrologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists specializing in hematology and transplant medicine; and any other healthcare professionals with an interest in or who may clinically encounter patients with aHUS.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 10, 2019
    • Expiration of CME credit: July 10, 2021